OGT settles legal action with Bioarray Solutions

Wednesday 21 January 2009

Oxford Gene Technology (OGT) is pleased to announce a settlement of the lawsuit it filed in the United States Federal Court for the District of Delaware against BioArray Solutions Ltd. of Warren, NJ in May 2008, for alleged infringement of OGT’s patent numbers US 6,307,039, US 6,770,751 and US 7,192,707. BioArray has consistently denied that it infringed.

As a result of the settlement, OGT entered into a licence agreement with BioArray, now part of Immucor, giving them worldwide rights in the field of molecular immunohaematology for Family 6 patents. These describe the use of microarray technology to detect variations in DNA sequences e.g. SNPs or different lengths of tandem repeat regions.

Dr Michael Bennett, Vice President Licensing and Patents at OGT, said: “We are delighted that the legal situation with BioArray is now resolved. At OGT, we operate a flexible licensing programme and we’re pleased to be able to include BioArray in that programme.”

The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park,

Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 1865 856828 ; F: +44 1865 848684 ; E: licensing@ogt.co.uk

W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine.  The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures

CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Find out more

For more information about any OGT product or service, please contact us.